Related Experiment Video

Updated: Jun 19, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Drug-eluting stent thrombosis

T Pilgrim1, S Windecker

  • 1Department of Cardiology, Bern University Hospital, Bern, Switzerland.

Minerva Cardioangiologica
|October 20, 2009
PubMed

Insights

Drug-eluting stents (DES) significantly reduce repeat procedures but carry a risk of stent thrombosis. Newer DES aim to improve healing and reduce this rare but serious complication.

Area of Science:

  • Cardiovascular Medicine
  • Biomedical Engineering
  • Interventional Cardiology

Background:

  • Drug-eluting stents (DES) offer significant benefits over bare metal stents, reducing repeat revascularization by 50-70%.
  • Stent thrombosis (ST), though rare, is a severe adverse event associated with coronary stents.
  • Very late stent thrombosis (VLST), occurring >1 year post-implantation, is a complicating factor specifically with DES.

Purpose of the Study:

  • To investigate the mechanisms underlying very late stent thrombosis (VLST) in drug-eluting stents (DES).
  • To identify factors contributing to VLST, particularly polymer components in DES.
  • To highlight the development of newer generation DES focused on enhanced vascular healing and neointimal suppression.

Main Methods:

  • Review of autopsy studies examining mechanisms of VLST.
  • Analysis of stent components, focusing on polymers in DES.
  • Evaluation of newer generation DES designs targeting improved vascular healing.

Main Results:

  • Delayed healing and incomplete re-endothelialization are identified as primary mechanisms for VLST.
  • Polymer components of DES are implicated as a significant factor in VLST.
  • Autopsy studies provide critical insights into the pathophysiology of VLST.

Conclusions:

  • VLST is a complex complication of DES, with delayed healing and incomplete re-endothelialization being key contributors.
  • The materials used in DES, especially polymers, play a role in the occurrence of VLST.
  • Next-generation DES are being developed to mitigate VLST risk by promoting better vascular healing and drug delivery.

More Related Videos

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention11:01

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Published on: September 18, 2015

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...